Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Supernus Pharmaceuticals has reported that a Phase IIa US clinical trial evaluating SPN-812 as a treatment for adults with attention deficit hyperactivity disorder (ADHD) met the primary endpoints of safety and tolerability.
Subscribe to our email newsletter
SPN-812 is a selective norepinephrine reuptake inhibitor, which, according to Supernus, could be more effective and have a better side effect profile than other non-stimulant treatments for ADHD due to its different pharmacological profile.
The study also demonstrated statistically significant median reduction versus placebo in both investigator-rated and patient-rated ADHD symptom scores.
The randomised, double-blind, placebo-controlled trial evaluated 53 adults with a current diagnosis of ADHD.
The primary endpoints were safety and tolerability, while the secondary endpoints included the efficacy of SPN-812, and the effectiveness of SPN-812 when compared to placebo.